Together, these results introduce compounds 4a and 4b as interesting new hits endowed with potential CDK2 inhibition and antiproliferative activity against CRC and HCC cell lines, HCT116 and HepG2. The gene discussed is CDK2; the disease is colorectal carcinoma.